Komori
Governance4502Takeda Pharmaceutical Company LimitedPharmaceuticals

Continuation in 2026 of the share-based compensation plan for the Company's directors and the share grant plan for the Company's domestic executives

The BIP trust for directors and the ESOP trust for domestic executives will continue in 2026, and the terms of both trusts will be extended by 3 years through the end of August 2029. An additional ¥800 million will be contributed to the BIP trust, while no additional contribution or share acquisition will be made for the ESOP trust.

Worth reading
35Immaterial
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
8
¥100 million (planned additional contribution to the BIP trust)
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee
Committee1
Compensation Committee: all members are outside directors (100%)
Changes this time

Continuation in 2026 of the stock-based compensation plan and stock grant plan. The terms of the BIP trust and ESOP trust established in 2023 will be extended by 3 years through the end of August 2029. An additional ¥800 million is planned to be contributed to the BIP trust, while no additional contribution or additional share acquisition will be made for the ESOP trust.

Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee
CommitteeCompensation Committee: all members are outside directors (100%)
Changes this timeContinuation in 2026 of the stock-based compensation plan and stock grant plan. The terms of the BIP trust and ESOP trust established in 2023 will be extended by 3 years through the end of August 2029. An additional ¥800 million is planned to be contributed to the BIP trust, while no additional contribution or additional share acquisition will be made for the ESOP trust.
Items this document does not state (5)
Number of directorsNumber of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

For directors, to increase awareness of the need to contribute to improving medium- to long-term performance and increasing corporate value; for outside directors and Audit & Supervisory Committee members, to increase awareness of sharing interests with shareholders and contributing to increased corporate value; and for domestic executives, to enhance medium- to long-term incentives and retention.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Continuation in 2026 of the share-based compensation plan for the Company's directors and the share grant plan for the Company's domestic executives | Takeda Pharmaceutical Company Limited (4502) timely disclosure | Komori